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Article focus
  Microbiological diagnosis of prosthetic 
joint infection (PJI) relies on culture techni­
ques that are slow and insensitive. Inflamm­
ation biomarkers such as calprotectin have 
the potential to rapidly diagnose infection. 
This pilot study tests the performance 
of a calprotectin lateral flow assay for 
the diagnosis of PJI using synovial fluid 
samples.
Key messages
  The lateral flow test has a high negative 
predictive value (NPv) compared to Inter­
national Consensus Meeting (ICM) crite­
ria, useful for ruling out infection. The test 
is highly accurate for diagnosing PJI when 
compared to a clinical review­based gold 
standard (ICM­CR).
  The test may be more accurate for diag­
nosing PJI in knees than in hips.
preliminary evaluation of a rapid lateral 
flow calprotectin test for the diagnosis of 
prosthetic joint infection
Aims
This pilot study tested the performance of a rapid assay for diagnosing prosthetic joint 
infection (pJI), which measures synovial fluid calprotectin from total hip and knee revision 
patients.
Methods
A convenience series of 69 synovial fluid samples from revision patients at the norfolk and 
norwich University Hospital were collected intraoperatively (52 hips, 17 knees) and frozen. 
synovial fluid calprotectin was measured retrospectively using a new commercially available 
lateral flow assay for pJI diagnosis (Lyfstone As) and compared to International consensus 
Meeting (IcM) 2018 criteria and clinical case review (IcM-cR) gold standards.
Results
According to IcM, 24 patients were defined as pJI positive and the remaining 45 were nega-
tive. The overall accuracy of the lateral flow test compared to IcM was 75.36% (52/69, 95% 
cI 63.51% to 84.95%), sensitivity and specificity were 75.00% (18/24, 95% cI 53.29% to 
90.23%) and 75.56% (34/45, 95% cI 60.46% to 87.12%), respectively, positive predictive 
value (ppV) was 62.07% (18/29, 95% cI 48.23% to 74.19%) and negative predictive value 
(npV) was 85.00% (34/40, 95% cI 73.54% to 92.04%), and area under the receiver oper-
ating characteristic (Roc) curve (AUc) was 0.78 (95% cI 0.66 to 0.87). patient data from 
discordant cases were reviewed by the clinical team to develop the IcM-cR gold standard. 
The lateral flow test performance improved significantly when compared to IcM-cR, with 
accuracy increasing to 82.61% (57/69, 95% cI 71.59% to 90.68%), sensitivity increasing 
to 94.74% (18/19, 95% cI 73.97% to 99.87%), npV increasing to 97.50% (39/40, 95% cI 
85.20% to 99.62%), and AUc increasing to 0.91 (95% cI 0.81 to 0.96). Test performance 
was better in knees (100.00% accurate (17/17, 95% cI 80.49% to 100.00%)) compared to 
hips (76.92% accurate (40/52, 95% cI 63.16% to 87.47%)).
Conclusion
This study demonstrates that the calprotectin lateral flow assay could be an effective diag-
nostic test for pJI, however additional prospective studies testing fresh samples are required.
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  Metallosis and severe osteolysis may be contraindica­
tions for use of the test.
Strengths and limitations
  all eligible samples (sufficient synovial fluid volume 
and sufficient data to make ICM diagnosis) were 
tested, avoiding any selection bias, and rapid test 
operators were blind to gold standard results.
  Samples were frozen and tested retrospectively and 
the number of knee samples tested was relatively low.
Introduction
each year in the uK, approximately 160,000 primary hip 
and knee arthroplasties are performed plus an additional 
14,000 revision operations. Prosthetic joint infection (PJI) 
is responsible for 14% of these revisions.1
diagnosis of PJI remains a challenge and guidelines vary 
between countries. low­grade PJIs are particularly difficult 
to diagnose. They are commonly caused by bacteria which 
do not have a clear pathogenic role and often contaminate 
tissue samples, making culture results difficult to inter­
pret.2 These organisms are also less likely to trigger an 
increase in inflammatory markers.3 The inability to differ­
entiate between low­grade infections and aseptic loosen­
ing leads to patients undergoing numerous investigations 
and unnecessary two­stage revisions. This treatment 
option comes with a higher cost both to the healthcare 
system and accompanying patient morbidity, along with 
an associated higher complication rate than one­stage 
revisions.4 for this group of patients especially there is a 
need for a diagnostic test that can reliably exclude PJI.
The Musculoskeletal Infection Society (MSIS) and 
International Consensus Meetings (ICMs) have pub­
lished lists of criteria designed to standardize the diag­
nosis of PJI.5–7 The criteria require a diagnostic workup 
combining preoperative and intraoperative findings 
with selected inflammatory markers and culture results. 
MSIS and ICM criteria are useful but fallible, due to 
the heavy weighting placed on microbiological culture 
results, which are known to have suboptimal specificity 
and sensitivity.8,9
In response to the rapid emergence of new biomarkers 
for PJI,10–12 the ICM criteria were revised to include serum 
d­dimer, synovial alpha­defensins, and synovial leuco­
cyte esterase in 2018.7 These tests can be expensive and 
their application in clinical practice is currently limited. 
an alternative biomarker is synovial fluid calprotectin. 
Calprotectin is a protein complex released during inflamm­
ation that makes up 60% of all soluble proteins in neutro­
phils.13 Neutrophils are recruited to sites of inflammation 
and infection response; therefore, high levels of neutro­
phil biomarkers are expected to be seen in infected 
patient samples.14
Calprotectin is routinely used to screen for inflamma­
tory bowel disease and has been shown to detect relapse 
rheumatoid arthritis.15,16 In a recent study, a stool calpro­
tectin test was used off label for PJI diagnosis, demonstr­
ating a NPv of 94.4%.17 This demonstrates the utility of 
calprotectin for PJI diagnosis and the need for a validated 
lateral flow test.
lyfstone aS (Tromsø, Norway) have recently devel­
oped a lateral flow calprotectin test for the diagnosis of 
PJI which has passed the european in vitro diagnostic 
(Ivd) regulatory approval process (98/79/eC). we con­
ducted the first clinical evaluation of this new technology 
in a retrospective study on samples from suspected PJI or 
aseptic loosening cases to assess the sensitivity, specific­
ity, NPv, and positive predictive value (PPv).
Methods
a total of 73 synovial fluid samples that had been 
stored in the Biorepository at the university of east 
anglia (Norwich, uK) between february 2016 and 
January 2019 were retrospectively tested for calprotec­
tin levels with the lyfstone calprotectin lateral flow test 
(lyfstone aS). Samples were intraoperative specimens 
from a consecutive series of patients during revision 
total hip and total knee arthroplasty surgery performed 
at the Norfolk and Norwich university hospital (NNuh; 
Norwich, uK). Samples were only placed in the Biorep­
ository if patient consent was obtained at the time of 
surgery and sufficient sample remained following rou­
tine clinical evaluation.
Samples were only included for testing with the 
lyfstone test if there was a sufficient volume (≥ 100 µl) 
and results for microbiological culture, frozen­section 
histology, and serum CRP were available. Subsequently, 
four samples were removed from the analysis due to 
incomplete/erroneous patient data (two had no preop­
erative notes and two were from a patient who had two 
separate surgeries, although the samples had the same 
date). a final total of 69 samples were included in the 
dataset (37 male, 32 female; mean age 74.3 years (45 to 
89); mean body mass index (BMI) 29.8 kg/m2 (19.7 to 
42.4)); 52 were taken during hip revision surgery and 17 
from knee revisions.
Cases were classified as either infected or aseptic based 
on the new definition of prosthetic hip and knee infection 
from the 2018 ICM, hereafter referred to as ‘ICM’ criteria 
(Table I). a case was deemed as infected if the patient 
presented either with a major criterion (two or more cul­
tures of the same organism or the presence of a sinus 
tract) or met three minor criteria (elevated serum CRP lev­
els, purulence, one positive microbiological culture, and/
or positive histological analysis of periprosthetic tissue for 
inflammation). other minor criteria from the 2018 ICM 
criteria were not considered as many of those tests are 
not used as standard in the uK or routinely at NNuh. 
Clinical information was not made available to performers 
of the index test before testing.
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Cases where the calprotectin result was discordant 
with the ICM diagnosis of infection were further investi­
gated by one of the senior authors (IM – Consultant 
orthopaedic Surgeon) and team (MS, ad). The team 
were blinded to the calprotectin result and were asked to 
review the patient medical records, surgical notes, and 
radiographs. as this was a retrospective examination by 
the team, contemporaneous records from the treating 
surgeon (IM, MS, ad) were reviewed to ascertain the 
clinical decisions made at the time, for example a patient 
who had met the criteria for infection with ICM by two 
positive microbiology samples may not have been treated 
for infection as it was thought that those bacteria were 
contaminants (following multidisciplinary team discuss­
ion with the microbiologist at the time). The longer­term 
clinical outcome of the patient was then reviewed using 
one­year follow­up notes to ascertain if the clinical deci­
sion had been justified. we classified these results as ICM 
with Clinical Review ­ ICM­CR (aseptic loosening was 
graded according to the Paprosky classification).18
The lyfstone calprotectin test was carried out accord­
ing to the manufacturer’s kit instructions (lyfstone aS). 
Synovial fluid samples (20 µl) were diluted in a premixed 
dilution buffer (2 ml – 101 × dilution) and added to the 
test cassette (80 µl). gold­conjugated antibody com­
plexes then bound calprotectin and travelled along the 
membrane within the cassette and further bound to 
immobilized calprotectin­specific antibodies to form a vis­
ible test line. any remaining gold­conjugated antibody 
not bound to calprotectin was immobilized on a control 
line. after 15 minutes’ incubation at room temperature 
the cassette was photoimaged, and the calprotectin level 
was calculated by the lyfstone smartphone application 
(lyfstone aS) (figure 1). The colour intensity of the test 
line was proportional to the concentration of calprotectin 
in the sample. a calprotectin result of ≤ 14 mg/l was con­
sidered negative according to the cutoff between low and 
moderate risk of infection by the lyfstone smartphone 
application at the time of testing. Moderate (14 mg/l to 
50 mg/l) and severe (> 50 mg/l) risk of infection catego­
ries were grouped together as positive.19
Microbiological culture was performed on all tissue 
and fluid specimens (recommended that three to five 
tissue/fluid samples sent for testing) for 48 hours on blood 
agar and chocolate agar, five days on fastidious anaerobe 
agar, and five days in cooked meat broth before 48­hour 
subculture on fastidious anaerobe agar, chocolate agar, 
sabouraud agar, and in fastidious antimicrobial neutraliza­
tion bottles according to the uK Standards for Microbiology 
Investigations B 44.20 histology was performed by frozen 
section microscopy according to uKaS ISo 8405.21 Serum 
CRP was performed according to uKaS ISo 10295.22
Statistical analysis. all statistical calculations were per­
formed using MedCalc Statistical Software version 19.1 
(MedCalc Software, ostend, Belgium). Statistical signifi­
cance was set at p < 0.05.
table I. Scoring­based definition for prosthetic joint infection using available tests from the 2018 International Consensus Meeting criteria
Criteria Score Decision
Major Infected
Two positive cultures of the same organism N/a  
Sinus tract with evidence of communication to the joint or visualization of the prosthesis N/a  
Minor ≥ 6 infected; < 6 aseptic
elevated serum CRP (≥ 10 mg/l) or d­dimer (d­dimer unavailable) 2  
Positive histology 3  
Positive purulence 3  
Single positive culture 2  
elevated serum eSR (unavailable) 1  
elevated synovial wBC count or le (unavailable) 3  
Positive alpha­defensin (unavailable) 3  
elevated synovial PMNs (%) (unavailable) 2  
elevated synovial CRP (unavailable) 1  
le, leucocyte esterase; N/a, not applicable; PMN, polymorphonuclear neutrophil; wBC, white blood cell.
Fig. 1
lyfstone application report (right) and lyfstone calprotectin test (left) (lyfs­
tone aS, Tromsø, Norway).
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table II. International Consensus Meeting and calprotectin test results. The red and green shading represent positive and negative results, respectively
Sample number Hip or knee Histology* Culture† CRP‡ Sinus tract§ Purulence¶ ICM** Calprotectin††
1 K negative negative 13 N N negative negative
2 h negative negative 40 N N negative negative
3 h negative negative N/a N N negative negative
4 h negative negative 2 N N negative positive
5 h positive negative 47 y y positive positive
6 h negative negative 2 N N negative negative
7 h negative negative 6 N N negative negative
8 K negative negative < 1 N N negative negative
9 h negative negative 7 N N negative negative
10 h negative negative 2 N N negative negative
11 h negative negative 7 N N negative positive
12 h negative negative 21 N N negative negative
13 h positive negative 35 y y positive positive
14 h negative negative < 1 N N negative positive
15 K N/a positive 69 y N positive positive
16 h negative negative 1 N N negative positive
17 h negative negative 4 N N negative negative
18 h N/a positive 87 N y positive negative
19 h N/a positive 101 N y positive positive
20 h negative negative 1 N N negative negative
21 K N/a positive 5 N N positive negative
22 h N/a positive 25 N N positive positive
23 h negative negative 10 N N negative negative
24 h negative negative 5 N N negative negative
25 K positive positive 286 N y positive positive
26 h N/a positive 44 y N positive positive
27 h negative negative 17 N N negative positive
28 h negative negative 1 N N negative positive
29 K negative negative 19 N N negative negative
30 h positive positive 61 N y positive positive
31 K negative negative N/a N N negative negative
32 h negative negative < 1 N N negative negative
33 h negative negative 6 N N negative negative
34 K positive positive 91 N N positive positive
35 h negative negative 5 N N negative positive
36 h negative negative 8 N N negative positive
37 h positive positive 114 N y positive positive
38 K negative negative < 1 N N negative negative
39 h negative negative 3 N N negative negative
40 h negative negative 1 N N negative negative
41 K negative negative 29 N N negative negative
42 h N/a positive 18 N N positive positive
43 h negative negative 1 N N negative negative
44 h negative negative 4 N N negative negative
45 h negative negative 2 N N negative negative
46 K N/a positive 219 N N positive positive
47 h negative negative < 1 N N negative negative
48 h negative positive < 1 N N positive negative
(Continued)
Results
Lyfstone test performance compared to ICM. The overall 
sensitivity and specificity of the calprotectin test for the 
diagnosis of PJI compared to ICM criteria were 75.00% 
(18/24, 95% CI 53.29% to 90.23%) and 75.56% (34/45, 
95% CI 60.46% to 87.12%), respectively. The PPv was 
62.07% (18/29, 95% CI 48.23% to 74.19%), the NPv 
was 85.00% (34/40, 95% CI 73.54% to 92.04%), and the 
accuracy was 75.36% (52/69, 95% CI 63.51% to 84.95%) 
(Tables II and III). The area under the receiver operating 
characteristic (RoC) curve (auC) was 0.78 (95% CI 0.66 
to 0.87) (figure 2).
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table III. Performance of calprotectin test on tested synovial fluid samples
Lyfstone* test Gold standard
ICM ICM-CR
 All samples (n = 69) Hips (n = 52) Knees (n = 17) All samples (n = 69) Hips (n = 52) Knees (n = 17)
Sensitivity, %  
(n/total n) (95% CI)
75.00 (18/24) (53.29 
to 90.23)
80.00 (12/15) 
(51.91 to 95.67)
66.67 (6/9) (29.93 
to 92.51)
94.74 (18/19) (73.97 
to 99.87)
92.31 (12/13) 
(63.97 to 99.81)
100.00 (6/6) 
(54.07 to 100.00)
Specificity, %  
(n/total n) (95% CI)
75.56 (34/45) (60.46 
to 87.12)
70.27 (26/37) 
(53.02 to 84.13)
100.00 (8/8) 
(63.06 to 100.00)
78.00 (39/50) (64.04 
to 88.47)
71.79 (28/39) 
(55.13 to 85.00)
100.00 (11/11) 
(71.51 to 100.00)
PPv, % (n/total n) 
(95% CI)
62.07 (18/29) (48.23 
to 74.19)
52.17 (12/23) 
(38.48 to 65.55)
100.00 (6/6) 
(100.00 to 100.00)
62.07 (18/29) (49.00 
to 73.60)
52.17 (12/23) 
(39.23 to 64.83)
100.00 (6/6) 
(100.00 to 100.00)
NPv, % (n/total n) 
(95% CI)
85.00 (34/40) (73.54 
to 92.04)
89.66 (26/29) 
(75.51 to 96.06)
72.73 (8/11) 
(51.42 to 87.04)
97.50 (39/40) (85.20 
to 99.62)
96.55 (28/29) 
(80.83 to 99.47)
100.00 (11/11) 
(100.00 to 100.00)
accuracy, %  
(n/total n) (95% CI)
75.36 (52/69) (63.51 
to 84.95)
73.08 (38/52) 
(58.98 to 84.43)
82.35 (14/17) 
(56.57 to 96.20)
82.61 (57/69) (71.59 
to 90.68)
76.92 (40/52) 
(63.16 to 87.47)
100.00 (17/17) 
(80.49 to 100.00)
*lyfstone aS, Tromsø, Norway.
CI, confidence interval; ICM, International Consensus Meeting 2018 criteria; ICM­CR, International Consensus Meeting 2018 criteria with clinical review; NPv, 
negative predictive value; PPv, positive predictive value.
Sample number Hip or knee Histology* Culture† CRP‡ Sinus tract§ Purulence¶ ICM** Calprotectin††
49 h negative negative 3 N N negative negative
50 K negative positive 4 N N positive negative
51 h positive negative 36 N y positive positive
52 h negative negative 2 N N negative negative
53 h negative negative < 1 N N negative positive
54 K negative negative 2 N N negative negative
55 K N/a positive 31 N N positive positive
56 h negative positive 30 N N positive negative
57 K negative positive 1 N N positive negative
58 h negative negative < 1 N N negative negative
59 h N/a positive 49 N y positive positive
60 K N/a positive 67 N y positive positive
61 h negative negative 3 N N negative negative
62 h N/a positive 284 y y positive positive
63 h negative negative 15 N N negative negative
64 h negative negative 4 N N negative negative
65 h negative negative 3 N N negative positive
66 K negative negative 6 N N negative negative
67 h positive negative 15 N N negative positive
68 h positive negative 3 N N negative negative
69 h N/a positive 51 y N positive positive
*Positive/negative for signs of inflammation by frozen section microscopy.
†Positive/negative for two or more cultures of the same organism from periprosthetic tissue and fluid samples.
‡Positive when serum CRP level ≥ 10 mg/l.
§y represents the presence of sinus tract.
¶y represents visible wound purulence.
**Positive/negative according to scoring in Table I.
††Positive when ≥ 14 mg/l synovial calprotectin measured by lyfstone calprotectin test (lyfstone aS, Tromsø, Norway).
ICM, International Consensus Meeting 2018 criteria; N/a, not available.
table II. (Continued)
a total of 24 cases were classed as infected (15 hips, 
nine knees) and 45 cases aseptic (37 hips, eight knees) 
according to ICM criteria. of the infected cases, 21 were 
found to be positive by routine microbiology alone (two 
or more cultures were positive for the same organism). 
Two of the remaining cases were found to be positive by 
histology and elevated serum CRP, and one positive cul­
ture (Collinsella aerofaciens and ‘diphtheroids’) and the 
remaining infected case were found positive by a combi­
nation of histology, CRP, and purulence (Table II).
In this infected group there were 18 true positive and 
six false negative results by calprotectin. The reported 
organisms in these false negative cases were Cutibacterium 
acnes (n = 3), Bacteroides fragilis (n = 1), Staphylococcus 
epidermidis (n = 1), and a polymicrobial infection of 
Pseudomonas aeruginosa with Corynebacterium tubercu-
lostearicum (n = 1).
The remaining 45 cases were found to be aseptic by ICM 
criteria, and of these 34 were true negative and 11 were 
false positive according to the calprotectin test. of the 11 
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false positive cases, one case was positive for inflammation 
by histology and elevated CRP and one was CRP positive 
without significant histology. The remaining nine false pos­
itive samples were negative for any ICM criteria tested.
In the hip revision surgery group (n = 52) the test had 
a sensitivity of 80.00% (12/15, 95% CI 51.91% to 95.67%) 
and specificity of 70.27% (26/37, 95% CI 53.02% to 
84.13%). The PPv and NPv were 52.17% (12/23, 95% CI 
38.48% to 65.55%) and 89.66% (26/29, 95% CI 75.51% 
to 96.06%), respectively, with an overall test accuracy of 
73.08% (38/52, 95% CI 58.98% to 84.43%). all 11 false 
positive results in the study were hip revisions. In the 
knee revision surgery group (n = 17) the test was 66.67% 
sensitive (6/9, 95% CI 29.93% to 92.51%) and 100.00% 
specific (8/8, 95% CI 63.06% to 100.00%). with no false 
positive results, the PPv was 100.00% (6/6, 95% CI 
100.00% to 100.00%) but the NPv was 72.73% (8/11, 
95% CI 51.42% to 87.04%) (Table III). overall test accu­
racy was higher than in the hip group at 82.35% (14/17, 
95% CI 56.57% to 96.20%).
Lyfstone test performance compared to ICM-CR. overall 
test accuracy compared to the ICM­CR was 82.61% 
(57/69, 95% CI 71.59% to 90.68%). Sensitivity and speci­
ficity were 94.74% (18/19, 95% CI 73.97% to 99.87%) 
and 78.00% (39/50, 95% CI 64.04% to 88.47%), respec­
tively, with PPv of 62.07% (18/29, 95% CI 49.00% to 
73.60%) and NPv of 97.50% (39/40, 95% CI 85.20% to 
99.62%) (Table III). auC compared to ICM­CR was 0.91 
(95% CI 0.81 to 0.96) (figure 3).
In the hip group, radiograph and medical record review 
revealed that five patients had metal­on­metal implants 
with evidence of an adverse reaction to metal debris. 
additionally, two patients had severe metal staining of tissue 
caused by wear of the acetabular component following 
wear of the polyethylene liner. The remaining four false 
positive cases had aseptic loosening listed as the initial 
indication for operation. Review of preoperative radio­
graphs and operation notes revealed pre­ and intraopera­
tive evidence of osteolysis in three out of four cases, to 
proximal femur or acetabulum (Table Iv).
one­year follow­up of the remaining unresolved case 
(patient 35) revealed that they were still experiencing 
pain in their joint and their CRP had risen from 5 mg/l to 
19 mg/l, indicating possible infection. however, this 
remains under investigation by the treating teams.
a total of 53 patients remained once metallosis and 
severe osteolysis cases had been removed from the data­
set. This improved the specificity, PPv, and overall accu­
racy of the test both against ICM and ICM­CR (Table v).
The three false negative results within the hip subset 
were all ICM­positive by culture alone (two or more 
cultures of the same organism). Patient 18 was culture­
positive for B. fragilis, isolated from all cultured tissue 
samples, along with a high CRP and noted joint puru­
lence. Calprotectin was recorded at 13.36 mg/l, which 
falls just below the threshold value for a positive result 
(≥ 14 mg/l) (Supplementary Table i). Sample 48 was 
culture­positive for C. acnes but negative by both histol­
ogy and CRP. The calprotectin test was negative with 0.0 
table IV. Paprosky femoral and acetabular classification of patients diag­
nosed with aseptic loosening and with high calprotectin levels reported
Sample number femur Acetabulum
4 IIIB I
27 I IIIa
28 II IIB
0
0
20
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ty 60
80
100
20 40 60
100-specificity
80 100
Fig. 3
area under the receiver operating characteristic (RoC) curve (auC) of lyfstone 
calprotectin test (lyfstone aS, Tromsø, Norway) against International Consen­
sus Meeting 2018 with clinical review criteria (ICM­CR) for infection. auC = 
0.905; p < 0.001.
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Fig. 2
area under the receiver operating characteristic (RoC) curve (auC) of the lyf­
stone calprotectin test (lyfstone aS, Tromsø, Norway) against International 
Consensus Meeting 2018 criteria (ICM) for infection. auC = 0.779; p < 0.001.
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mg/l. The initial indication for operation for this case was 
aseptic loosening and a single­stage revision was per­
formed. The C. acnes report was dismissed as contamina­
tion and the patient was not treated for infection. 
one­year follow­up of the patient showed no signs of 
infection indicating that the calprotectin result correlated 
with the clinical findings. Sample 56 was a similar case of 
an aseptic loosening revision yielding significant culture 
results (P. aeruginosa and C. tuberculostearicum) but with 
no detectable synovial fluid calprotectin. The patient had 
a single­stage revision and upon a two­month follow­up 
showed no sign of infection, indicating a true negative 
calprotectin result.
The clinical review (ICM­CR) increases the sensitivity of 
the lyfstone test from 75.00% (18/24, 95% CI 53.29% to 
90.23%) to 94.74% (18/19, 95% CI 73.97% to 99.87%) 
(Table III).
In the knee group, three false negative results were 
recorded; two cases of C. acnes and one case reporting 
S. epidermidis. Both C. acnes cases (samples 50 and 57) 
were patients displaying no preoperative indication of 
infection and were treated as aseptic loosening. The clini­
cal review found no complications after patient follow­
up, suggesting that both cases were aseptic and that the 
calprotectin results were correct. Sample 21 (S. epider-
midis) was taken during the second stage of revision sur­
gery performed one year after the first­stage operation. 
Clinical review revealed that the patient was originally 
treated for gross infection. at the time of the second­
stage revision, the patient showed no overt signs of infec­
tion, so treatment progressed to implantation of the 
prosthesis. Postoperative microbiology grew a culture of 
S. epidermidis from three out of six samples taken at the 
time of surgery. at the one­year follow­up the patient 
presented no sign of infection, confirming the calprotec­
tin result to be correct thus far. overall, the lyfstone test 
was 100% accurate for the diagnosis of PJI in knee sam­
ples (n = 17; Tables II and III).
Discussion
PJI is a serious complication of arthroplasty with associ­
ated patient morbidity and a substantial economical bur­
den of treatment.23,24 Microbiological culture techniques 
are slow and insensitive8,9 and although new diagnostic 
tests are being developed, none of the current methods 
are capable of reliably diagnosing PJI.5,25
Rapid biomarker­based tests have the potential to 
assist clinicians in making a preoperative diagnosis. early 
differentiation of PJI from aseptic loosening may reduce 
the number of unnecessary two­stage revisions per­
formed on patients with a presumptive diagnosis of low­
grade infection.
The Synovasure test (Zimmer Biomet, warsaw, Indiana, 
uSa) functions very similarly to the lyfstone calprotectin 
test, measuring another neutrophil­released antimicro­
bial peptide, α­defensin. Studies using Synovasure have 
shown varying results with sensitivities ranging from 
67.0% to 100.0% and specificities ranging from 82.4% to 
100.0% against the MSIS/ICM criteria.26–35 a systematic 
review summarizing the results of seven prospective trials 
found that the Synovasure lateral flow test had a mean 
sensitivity of 85% and a mean specificity of 90%.36
Recent studies on using calprotectin to diagnose PJI 
either using an enzyme­linked immunosorbent assay 
(elISa) method or an off­label lateral flow assay for meas­
uring faecal calprotectin have shown similar diagnostic 
performance. wouthuyzen­Bakker et al17,37 applied a fae­
cal calprotectin test to PJI, demonstrating a sensitivity of 
89% and a specificity of 90% in a pilot study37 and 86.7% 
and 91.6% in a follow­on study.17 a more recent study by 
Salari et al38 reported a sensitivity of 100% and a specificity 
of 95% utilizing an elISa­based calprotectin test. The 
lyfstone calprotectin lateral flow test piloted here demonst­
rates a sensitivity of 75.00% and a specificity of 75.56% 
using similar gold standard diagnostic criteria. our study is 
of a comparable size (69 samples compared to 6137, 52,17 
and 7638) and featured a similar prevalence of infected 
samples (35% compared to 31%37, 29%,17 and 37%38), 
but the sensitivity and specificity of the lateral flow assay is 
lower than previous calprotectin­based studies have 
shown. however, similar differences in performance have 
been reported between the Synovasure α­defensin lateral 
flow test and the α­defensin elISa method.39
Clinical review of discordant cases revealed that the 
low specificity of the calprotectin lateral flow test was 
associated with metallosis (7/11 false positive cases). 
Removing these samples increases the specificity from 
75.56% to 83.78%. The use of biomarker­based diag­
nostic tests is known to be unreliable in patients with 
metal­on­metal implants as these can cause gross inflamm­
ation producing false positive results.40,41 Severe osteo­
lysis can cause false positive results for the same reason 
and removing patients with severe osteolysis (n = 3) 
from the analysis further increased specificity to 96.88%, 
which is more in line with other published calprotectin 
table V. Performance of calprotectin test on tested synovial fluid samples, 
excluding metallosis and severe osteolysis cases
Lyfstone* test Gold standard
 ICM (n = 53)† ICM-CR‡
Sensitivity, % (95% CI) 71.43 (47.82 to 88.72) 93.75 (69.77 to 99.84)
Specificity, % (95% CI) 96.88 (83.78 to 99.92) 97.30 (85.84 to 99.93)
PPv, % (95% CI) 93.75 (68.14 to 99.06) 93.75 (68.36 to 99.05)
NPv, % (95% CI) 83.78 (72.37 to 91.06) 93.70 (84.36 to 99.59)
accuracy, % (95% CI) 86.79 (74.66 to 94.52) 96.23 (87.02 to 99.54)
*lyfstone aS, Tromsø, Norway.
†Calprotectin result against International Consensus Meeting criteria (n = 
53) for infection excluding all samples associated with metallosis and severe 
osteolysis.
‡Calprotectin result against International Consensus Meeting criteria (n = 
53) for infection with discrepant samples investigated by clinical follow­up 
excluding all samples associated with metallosis and severe osteolysis.
CI, confidence interval; ICM, International Consensus Meeting 2018 criteria; 
ICM­CR, International Consensus Meeting 2018 criteria with clinical review; 
NPv, negative predictive value; PPv, positive predictive value.
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studies (notably Salari et al38 excluded patients with 
metal­on­metal implants).
The clinical review also revealed that five out of six false 
negative results were in samples where the organisms 
detected by culture could be considered contaminants. 
Three of the six false negative samples were positive for C. 
acnes by culture. This organism is a common laboratory 
contaminant and not typically considered a cause of PJI 
when isolated from hip or knee tissues.42–44 only one false 
negative case was deemed a genuine infection by clinical 
review (case 18) in which the calprotectin result was very 
close to positive (13.36 mg/l, < 1 mg/l below the positive 
cutoff). If future optimization of the test sets a lower 
threshold value for infection, then this case would have 
been classified as positive. Such a readjustment of the cal­
protectin cutoff values may improve test performance in 
detecting low­grade infections.
The sensitivity and specificity of 93.75% and 97.30% 
after clinical review are consistent with other studies on 
calprotectin. differences in inclusion criteria, sample coll­
ection, and microbiology techniques applied in other 
studies may explain differences in performance observed. 
observed test accuracy was different for hip and knee 
revisions. false positive results were only observed in hip 
revisions, likely affected by the absence of metal­on­metal 
reactions in the knee revision group. while the test accu­
racy for knee revisions compared to ICM­CR was 100%, 
the sample size is small (17 revisions, eight positive for 
infection) and the 95% CIs are too wide (sensitivity CI 
54.07% to 100.00%; specificity CI 71.51% to 100.00%) 
to draw conclusions with high confidence. as such, more 
data are required to confirm these findings.
The study was limited by the use of retrospective sam­
ples. however, by testing all eligible samples in the Biorep­
ository we believe that we did not introduce any sample 
selection bias. The relatively small sample size has resulted 
in wide 95% CIs throughout, hence larger studies are 
required to confirm study findings. another limitation 
was that the samples had been frozen for storage before 
testing and the freeze­thaw process may have resulted in 
leucocyte cell lysis and an increase in calprotectin. as the 
test is validated for use on fresh synovial fluid samples, the 
recommended cutoffs may not necessarily be appropriate 
for our samples. It is worth noting that blood contamina­
tion of the samples had no impact on the accuracy of the 
test results, something the Synovasure lateral flow test 
warns may lead to false negative results.45
In conclusion, the lyfstone calprotectin lateral flow 
test shows good potential as a rapid diagnostic for 
infected arthroplasty cases. The high NPv makes this a 
potentially powerful rule­out test for infection in sus­
pected PJI. however, larger prospective studies, using 
consecutive samples from patients undergoing revision 
of all synovial joint arthroplasties, are required to more 
accurately define the test’s diagnostic performance.
Supplementary Material
Table showing additional patient data including 
number of samples organisms isolated from, and 
calprotectin test scores by risk category and quantifica­
tion in mg/l, sex, age, body mass index (BMI), location of 
operation, indication for operation, procedure under­
taken, and any relevant past medical history.
References
 1. No authors listed. HQIP. National Joint Registry 15th Annual Report. 2018. https://
www.hqip.org.uk/resource/national-joint-registry-15th-annual-report-2018/ (date 
last accessed 3 February 2020).
 2. Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27(2): 
302-345.
 3. Pérez-Prieto D, Portillo ME, Puig-Verdié L, et al. C-reactive protein may 
misdiagnose prosthetic joint infections, particularly chronic and low-grade infections. 
Int Orthop. 2017;41(7):1315-1319.
 4. Siedlecki C, Beaufils P, Lemaire B, Pujol N. Complications and cost of single-
stage vs. two-stage bilateral unicompartmental knee arthroplasty: A case-control 
study. Orthop Traumatol Surg Res. 2018;104(7):949-953.
 5. Parvizi J, Zmistowski B, Berbari EF, et al. New definition for periprosthetic joint 
infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop 
Relat Res. 2011;469(11):2992-2994.
 6. Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of 
America. Executive summary: diagnosis and management of prosthetic joint 
infection: clinical practice guidelines by the Infectious Diseases Society of America. 
Clin Infect Dis. 2013;56(1):1-10.
 7. Parvizi J, Tan TL, Goswami K, et al. The 2018 Definition of Periprosthetic Hip 
and Knee Infection: An Evidence-Based and Validated Criteria. J Arthroplasty. 
2018;33(5):1309-1314.e2.
 8. Boyle KK, Wood S, Tarity TD. Low-Virulence Organisms and Periprosthetic Joint 
Infection-Biofilm Considerations of These Organisms. Curr Rev Musculoskelet Med. 
2018;11(3):409-419.
 9. Parvizi J, Erkocak OF, Della Valle CJ. Culture-negative periprosthetic joint 
infection. J Bone Joint Surg Am. 2014;96-A(5):430-436.
 10. Deirmengian C, Kardos K, Kilmartin P, Cameron A, Schiller K, Parvizi J. 
Combined measurement of synovial fluid α-Defensin and C-reactive protein levels: 
highly accurate for diagnosing periprosthetic joint infection. J Bone Joint Surg Am. 
2014;96-A(17):1439-1445.
 11. Sousa R, Serrano P, Gomes Dias J, Oliveira JC, Oliveira A. Improving the 
accuracy of synovial fluid analysis in the diagnosis of prosthetic joint infection with 
simple and inexpensive biomarkers: C-reactive protein and adenosine deaminase. 
Bone Joint J. 2017;99-B(3):351-357.
 12. Tarabichi M, Fleischman AN, Shahi A, Tian S, Parvizi J. Interpretation of 
Leukocyte Esterase for the Detection of Periprosthetic Joint Infection Based on 
Serologic Markers. J Arthroplasty. 2017;32(9S):S97-S100.e1.
 13. Stríz I, Trebichavský I. Calprotectin - a pleiotropic molecule in acute and chronic 
inflammation. Physiol Res. 2004;53(3):245-253.
 14. Witter AR, Okunnu BM, Berg RE. The Essential Role of Neutrophils during Infect-
ion with the Intracellular Bacterial Pathogen Listeria monocytogenes. J Immunol. 
2016;197(5):1557-1565.
 15. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of 
patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 
2010;341:c3369.
 16. Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid 
arthritis: a systematic review. J Rheumatol. 2015;42(5):760-770.
 17. Wouthuyzen-Bakker M, Ploegmakers JJW, Ottink K, et al. Synovial 
Calprotectin: An Inexpensive Biomarker to Exclude a Chronic Prosthetic Joint 
Infection. J Arthroplasty. 2018;33(4):1149-1153.
 18. Paprosky WG, Perona PG, Lawrence JM. Acetabular defect classification 
and surgical reconstruction in revision arthroplasty. A 6-year follow-up evaluation. 
J Arthroplasty. 1994;9(1):33-44.
 19. No authors listed. LYFCLP005 Lateral Flow Test Kit Instructions For Use. Lyfstone AS.
 20. No authors listed. UK Standards for Microbiology Investigations: Investigation 
of orthopaedic implant associated infections. Public Health England. 2016. https://
assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_
data/file/504319/B_44i2.pdf (date last accessed 27 February 2020).
210 a. J. TRoTTeR, R. deaN, C. e. whITehouSe, eT al.
BONE & JOINT RESEARCH
 21. No authors listed. UKAS Medical ISO 8405. Service UKA. https://www.ukas.com/
wp-content/uploads/schedule_uploads/00007/8405%20Medical%20Single.pdf 
(date last accessed 27 February 2020).
 22. No authors listed. UKAS Medical ISO 10295. Service UKA. 2018. https://www.
ukas.com/wp-content/uploads/schedule_uploads/00007/10295%20Medical%20
Single.pdf (date last accessed 28 February 2020).
 23. Berend KR, Lombardi AV Jr, Morris MJ, Bergeson AG, Adams JB, Sneller MA. 
Two-stage treatment of hip periprosthetic joint infection is associated with a high rate 
of infection control but high mortality. Clin Orthop Relat Res. 2013;471(2):510-518.
 24. Barrack RL, Burnett RS, Sharkey P, Parvizi J. Diagnosing an infection: an 
unsolved problem. Orthopedics. 2007;30(9):777-778.
 25. Fernández-Sampedro M, Fariñas-Alvarez C, Garces-Zarzalejo C, et al. 
Accuracy of different diagnostic tests for early, delayed and late prosthetic joint 
infection. BMC Infect Dis. 2017;17(1):592.
 26. Berger P, Van Cauter M, Driesen R, Neyt J, Cornu O, Bellemans J. Diagnosis 
of prosthetic joint infection with alpha-defensin using a lateral flow device: a 
multicentre study. Bone Joint J. 2017;99-B(9):1176-1182.
 27. Bingham J, Clarke H, Spangehl M, Schwartz A, Beauchamp C, Goldberg 
B. The alpha defensin-1 biomarker assay can be used to evaluate the potentially 
infected total joint arthroplasty. Clin Orthop Relat Res. 2014;472(12):4006-4009.
 28. Eriksson HK, Nordström J, Gabrysch K, Hailer NP, Lazarinis S. Does the 
Alpha-defensin Immunoassay or the Lateral Flow Test Have Better Diagnostic 
Value for Periprosthetic Joint Infection? A Meta-analysis. Clin Orthop Relat Res. 
2018;476(5):1065-1072.
 29. Frangiamore SJ, Gajewski ND, Saleh A, Farias-Kovac M, Barsoum WK, 
Higuera CA. α-Defensin Accuracy to Diagnose Periprosthetic Joint Infection-Best 
Available Test? J Arthroplasty. 2016;31(2):456-460.
 30. Gehrke T, Lausmann C, Citak M, Bonanzinga T, Frommelt L, Zahar A. The Accuracy 
of the Alpha Defensin Lateral Flow Device for Diagnosis of Periprosthetic Joint Infection: 
Comparison with a Gold Standard. J Bone Joint Surg Am. 2018;100-A(1):42-48.
 31. Kasparek MF, Kasparek M, Boettner F, Faschingbauer M, Hahne J, Dominkus 
M. Intraoperative Diagnosis of Periprosthetic Joint Infection Using a Novel Alpha-
Defensin Lateral Flow Assay. J Arthroplasty. 2016;31(12):2871-2874.
 32. Riccio G, Cavagnaro L, Akkouche W, Carrega G, Felli L, Burastero G. Qualitative 
Alpha-defensin Versus The Main Available Tests For The Diagnosis Of Periprosthetic 
Joint Infection: Best Predictor Test? J Bone Jt Infect. 2018;3(3):156-164.
 33. Sigmund IK, Yermak K, Perka C, Trampuz A, Renz N. Is the Enzyme-linked 
Immunosorbent Assay More Accurate Than the Lateral Flow Alpha Defensin Test 
for Diagnosing Periprosthetic Joint Infection? Clin Orthop Relat Res. 2018;476(8): 
1645-1654.
 34. Stone WZ, Gray CF, Parvataneni HK, et al. Clinical Evaluation of Synovial Alpha 
Defensin and Synovial C-Reactive Protein in the Diagnosis of Periprosthetic Joint 
Infection. J Bone Joint Surg Am. 2018;100-A(14):1184-1190.
 35. Kleiss S, Jandl NM, Novo de Oliveira A, Ruther W, Niemeier A. Diagnostic 
accuracy of alpha-defensin enzyme-linked immunosorbent assay in the clinical 
evaluation of painful hip and knee arthroplasty with possible prosthetic joint 
infection: a prospective study of 202 cases. Bone Joint J. 2019;101-B(8):970-977.
 36. Marson BA, Deshmukh SR, Grindlay DJC, Scammell BE. Alpha-defensin and 
the Synovasure lateral flow device for the diagnosis of prosthetic joint infection: a 
systematic review and meta-analysis. Bone Joint J. 2018;100-B(6):703-711.
 37. Wouthuyzen-Bakker M, Ploegmakers JJW, Kampinga GA, Wagenmakers-
Huizenga L, Jutte PC, Muller Kobold AC. Synovial calprotectin: a potential 
biomarker to exclude a prosthetic joint infection. Bone Joint J. 2017;99-B(5):660-665.
 38. Salari P, Grassi M, Cinti B, Onori N, Gigante A. Synovial Fluid Calprotectin for the 
Preoperative Diagnosis of Chronic Periprosthetic Joint Infection. J Arthroplasty. 2019.
 39. Suen K, Keeka M, Ailabouni R, Tran P. Synovasure ‘quick test’ is not as accurate 
as the laboratory-based alpha-defensin immunoassay: a systematic review and meta-
analysis. Bone Joint J. 2018;100-B(1):66-72.
 40. Drummond J, Tran P, Fary C. Metal-on-Metal Hip Arthroplasty: A Review of 
Adverse Reactions and Patient Management. J Funct Biomater. 2015;6(3):486-499.
 41. Bonanzinga T, Zahar A, Dütsch M, Lausmann C, Kendoff D, Gehrke T. How 
Reliable Is the Alpha-defensin Immunoassay Test for Diagnosing Periprosthetic Joint 
Infection? A Prospective Study. Clin Orthop Relat Res. 2017;475(2):408-415.
 42. Both A, Klatte TO, Lübke A, et al. Growth of Cutibacterium acnes is common on 
osteosynthesis material of the shoulder in patients without signs of infection. Acta 
Orthop. 2018;89(5):580-584.
 43. Levy PY, Fenollar F, Stein A, et al. Propionibacterium acnes postoperative shoulder 
arthritis: an emerging clinical entity. Clin Infect Dis. 2008;46(12):1884-1886.
 44. Patel A, Calfee RP, Plante M, Fischer SA, Green A. Propionibacterium acnes 
colonization of the human shoulder. J Shoulder Elbow Surg. 2009;18(6):897-902.
 45. No authors listed. Zimmer Biomet. Diagnostics C. Synovasure Alpha Defensin 
Lateral Flow Test Kit: Instructions For Use. https://cddiagnostics.com/instructions/
PDF/LF%20Test%20Kit%20IFUs/EN_M40004B_V6_Synovasure_Alpha_Defensin_
Lateral_Flow_IFU.pdf (date last accessed 3 February 2020).
Author information
  a. J. Trotter, BSc (hons), MScR, Phd Student, university of east anglia, Norwich, uK, 
Quadram Institute Bioscience, Norwich Research Park, Norwich, uK.
  R. dean, MRes, Medical Student, university of east anglia, Norwich, uK, Quadram 
Institute Bioscience, Norwich Research Park, Norwich, uK.
  C. e. whitehouse, RgN, orthopaedic Clinical Research Nurse, Norfolk and Norwich 
university hospitals foundation Trust, Norwich, uK.
  J. Mikalsen, Cand. Scient, Phd, MBa, Chief Science officer (CSco), lyfstone aS, 
Tromsø, Norway.
  C. hill, BSc, Phd Student, Quadram Institute Bioscience, Norwich Research Park, 
Norwich, uK, Norfolk and Norwich university hospitals foundation Trust, Norwich, uK.
  R. Brunton­Sim, Research Consent lead, Norfolk and Norwich university hospitals 
foundation Trust, Norwich, uK.
  g. l. Kay, BSc, MRes, Phd, Senior Research Scientist, Quadram Institute Bioscience, 
Norwich Research Park, Norwich, uK.
  M. Shakokani, MBBS, fRCS (orth), Consultant Trauma and orthopaedic Surgeon, 
west Suffolk hospital, Bury St edmunds, uK.
  a. Z. e. durst, MB ChB, BSc (hons), MRCS, Speciality Registrar, associate Tutor, 
university of east anglia, Norwich, uK, Norfolk and Norwich university hospitals 
foundation Trust, Norwich, uK. 
  J. wain, BSc, MSc, Phd, group leader, Professor, university of east anglia, Norwich, 
uK, Quadram Institute Bioscience, Norwich Research Park, Norwich, uK.
  I. McNamara, Ma (Cantab), MRCP, fRCS (Tr and orth), Md, Consultant orthopaedic 
Surgeon, honorary Professor, university of east anglia, Norwich, uK, Norfolk and 
Norwich university hospitals foundation Trust, Norwich, uK.
  J. o’grady, BSc, MSc, Phd, group leader, associate Professor, university of east 
anglia, Norwich, uK, Quadram Institute Bioscience, Norwich Research Park, 
Norwich, uK.
Author contributions
  a. J. Trotter, designed the research, Tested the samples, analyzed the statistics, 
wrote and reviewed the manuscript.
  R. dean: Tested the samples, acquired the clinical data, wrote and reviewed the 
manuscript.
  C. e. whitehouse: acquired the clinical data, Identified, acquired consent for, and 
collected the samples, Reviewed the manuscript.
  J. Mikalsen: designed the research, Provided the training and support, Reviewed 
the manuscript.
  C. hill: Identified, acquired consent for, and collected the samples, Reviewed the 
manuscript.
  R. Brunton­Sim: Tested the samples, acquired the clinical data, Reviewed the 
manuscript.
  g. l. Kay: wrote and reviewed the manuscript.
  M. Shakokani: Identified, acquired consent for, and collected the samples, Reviewed 
the manuscript.
  a. Z. e. durst: Identified, acquired consent for, and collected the samples, Reviewed 
the manuscript.
  J. wain: Performed the clinical management and setup of the trial, Reviewed the 
manuscript.
  I. McNamara: designed the research, Conducted the patient reviews, Performed the 
clinical management and setup of the trial, wrote and reviewed the manuscript.
  J. o’grady: designed the research, wrote and reviewed the manuscript.
Funding statement
  J. Mikalsen reports payment from lyfstone aS during the course of this study, and a 
pending International Patent application (No. PCT/eP2018/053044).
  J. o’grady and J. wain report accommodation expenses paid by lyfstone aS for a 
project meeting in Tromsø, Norway in relation to this study.
  a. J. Trotter reports travel expenses paid by lyfstone aS for a conference related 
to this study. I. McNamara reports a grant and personal consultancy fees from 
lyfstone aS for advice on diagnosis and treatment of prosthetic joint infection in 
relation to this study.
  This paper presents independent research funded by orthopaedic Research uK 
(oRuK – grant number 526) and the Biotechnology and Biological Sciences 
Research Council (BBSRC) Institute Strategic Programme Microbes in the food 
Chain BB/R012504/1 and its constituent projects BBS/e/f/000PR10348 and BBS/
e/f/000PR10349 (Jog).
  The author or one or more of the authors have received or will receive benefits for 
personal or professional use from a commercial party related directly or indirectly 
to the subject of this article.
conflict of interest statement
  None declared
Acknowledgements
  I. McNamara and J. o’grady contributed equally to this study.
ethical review statement
  ethical approval was provided by university of east anglia, faculty of Medicine 
and health Sciences Research ethics Committee, project reference: 2016/1721Se. 
Informed consent was obtained from all patients included in the study.
©2020 Author(s) et al. This is an open­access article distributed under the terms of 
the Creative Commons attribution Non­Commercial No derivatives (CC By­NC­Nd 4.0) 
licence, which permits the copying and redistribution of the work only, and provided 
the original author and source are credited. See https://creativecommons.org/licenses/
by­nc­nd/4.0/.
